Works matching IS 11750561 AND DT 2020 AND VI 21 AND IP 4


Results: 13
    1
    2

    Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.

    Published in:
    American Journal of Clinical Dermatology, 2020, v. 21, n. 4, p. 567, doi. 10.1007/s40257-020-00527-x
    By:
    • Beck, Lisa A.;
    • Thaçi, Diamant;
    • Deleuran, Mette;
    • Blauvelt, Andrew;
    • Bissonnette, Robert;
    • de Bruin-Weller, Marjolein;
    • Hide, Michihiro;
    • Sher, Lawrence;
    • Hussain, Iftikhar;
    • Chen, Zhen;
    • Khokhar, Faisal A.;
    • Beazley, Bethany;
    • Ruddy, Marcella;
    • Patel, Naimish;
    • Graham, Neil M. H.;
    • Ardeleanu, Marius;
    • Shumel, Brad
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13